

**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
	)	
Borberg <i>et al.</i>	)	
	)	Art Unit: Unassigned
Application No.: 10/649,968	)	
	)	
Filing Date: August 26, 2003	)	Examiner: Unassigned
	)	
For: METHOD FOR TREATMENT DISEASES	)	
ASSOCIATED WITH A DETERIORATION	)	Confirmation No. Unassigned
OF THE MACROCIRCULATION,	)	
MICROCIRCULATION AND ORGAN	)	
PERFUSION	)	

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.  
Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Form PTO-1449 is a listing of documents known to Applicants and/or their attorneys. The documents cited with an asterisk (\*) were cited by or submitted to the Patent Office in U.S. Application No. 09/095,472, filed June 10, 1998, to which the present application claims priority. Pursuant to 37 C.F.R. § 1.98(d), copies of these documents are not enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(1)(3), in that a first Office Action on the merits in the present patent application has not yet been mailed to Applicants.


**ATTORNEY DOCKET NO. 07030.0004U2**  
**APPLICATION NO. 10/649,968**

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed to be due; however, the Commissioner is hereby authorized to charge any fees which may be required or to credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




Bruce H. Becker, M.D.  
Registration No. 48,884

NEEDLE & ROSENBERG, P.C.  
Customer Number 23859  
(678) 420-9300 (phone)  
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.



Bruce H. Becker, M.D.

3/5/04

Date



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>LIST OF INFORMATION CITED BY APPLICANT</b> (Use as many sheets as necessary)				Complete if Known			
				Application Number		10/649,968	
				Filing Date		August 26, 2003	
				First Named Inventor		Borberg	
				Art Unit		Unassigned	
Examiner Name		Unassigned					
<b>U.S. PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	*A1	6,245,038 B1	06/12/2001	Borberg et al.	604	5.01	
	*A2	6,235,500 B1	05/22/2001	Sligar et al.	435	69.6	
	*A3	6,039,946	03/21/2000	Strahilevitz	424	140.1	
	*A4	5,944,684	08/31/1999	Roberts et al.	604	5	
	*A5	5,919,369	07/06/1999	Ash	210	645	
	*A6	5,911,698	06/15/1999	Cham	604	4	
	*A7	5,773,384	06/30/1998	Davankov et al.	502	402	
	*A8	5,753,227	05/19/1998	Strahilevitz	424	140.1	
	*A9	5,649,903	07/22/1997	Deniega et al.	604	4	
	*A10	5,554,293	09/10/1996	Uhoch	210	650	
	*A11	5,277,820	01/11/1994	Ash	210	646	
	*A12	5,171,456	12/15/1992	Hwang et al.	210	782	
	*A13	5,112,298	05/12/1992	Prince et al.	604	6	
	*A14	4,900,720	02/13/1990	Kotitschke	514	21	
	*A15	4,830,849	05/16/1989	Osterholm	424	2	
	*A16	4,685,900	08/11/1987	Honard et al.	604	5	
	*A17	4,643,718	02/17/1987	Marten	604	4	
	*A18	4,350,156	09/21/1982	Malchesky et al.	128	214	
	*A19	4,103,685	08/01/1978	Lupien et al.	128	214	
	*A20	3,933,998	01/20/1976	Seidehamel et al.	424	28	
	*A21	3,727,612	04/17/1973	Sayers et al.	128	214	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No		
<b>NON-PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)					
	*A22	Brunner et al., "Change in hemorrheological and biochemical parameters following membrane differential filtration." <i>Int. J. Artif. Organs</i> 18(12):794-798 (December 1995)					

	*A23	Brunner et al., "Clinical efficacy of haemorheological treatment using plasma exchange, selective adsorption and membrane differential filtration in maculopathy, retinal vein occlusion and uveal effusion syndrome," <i>Transfus. Sci.</i> 17(4):493-498 (December 1996)
	*A24	Brunner et al., "Erythrocyte apheresis in combination with elimination of fibrinogen and plasma proteins of higher molecular weight in macular disease and in uveal effusion syndrome." <i>Acta Medica Austriaca</i> 18(Suppl. 1):63-65 (January 1991)
	*A25	Brunner et al., "Plasma exchange and immunoglobulins in the treatment of intermediate uveitis." <i>Dev. Ophthalmol.</i> , Karger (Public.) Basel 23:275-284 (1992)
	*A26	Gavrilov, "The assessment of the antithrombotic effect of plasma and platelet apheresis as part of combined treatment for unstable angina," <i>Kardiologiya</i> 28(5):60-64 (May 1988)
	A27	Georgazde et al., "Plasmapheresis in the treatment of critical degrees of ischaemia in diabetic and angiopathies of lower extremities," <i>Vestn Khir Im I I Grek</i> 142(3):20-24 (March 1989) (English translation of article)
Examiner Signature:		Date Considered:
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		